Company Description
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
VolitionRx Limited is based in Henderson, Nevada.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Cameron Reynolds |
Contact Details
Address: 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 United States | |
| Phone | 646 650 1351 |
| Website | volition.com |
Stock Details
| Ticker Symbol | VNRX |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000093314 |
| CUSIP Number | 928661107 |
| ISIN Number | US9286611077 |
| Employer ID | 91-1949078 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jasmine Kway Ph.D. | Chief Executive Officer of Singapore Volition |
| Cameron Reynolds MBA | Founder, Chief Executive Officer, President and Director |
| Dr. Gaetan Michel Ph.D. | Chief Operating Officer |
| Terig Hughes | Chief Financial Officer and Treasurer |
| Dr. Jacob Vincent Micallef MBA, Ph.D. | Chief Scientific Officer |
| Nicholas Plummer | Group General Counsel |
| Louise Batchelor Day | Group Chief Marketing and Communications Officer |
| Gael Forterre M.B.A. | Chief Commercial Officer |
| Sharon Ballesteros | U.S. Head of Quality and Development Process |
| Rodney Gerard Rootsaert LLB | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2026 | 8-K | Current Report |
| Feb 19, 2026 | EFFECT | Notice of Effectiveness |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 11, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 9, 2026 | 8-K | Current Report |
| Feb 9, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 28, 2026 | D/A | Filing |
| Jan 26, 2026 | PRE 14A | Other preliminary proxy statements |
| Jan 8, 2026 | 8-K | Current Report |